Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VOTRIENT
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
- Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia
- Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
- Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
- Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
- Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
- Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
- Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
- SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
- Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
- A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
- Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
- Evaluation of Votrient in Angiosarcoma
- Pazopanib Maintenance Phase II
- Pazopanib vs. Pazopanib Plus Gemcitabine
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Pazopanib Tolerability When Given With Food
- Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
- PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
- Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
- Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
- Pazopanib Maintenance for SCLC
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
- Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
- Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
- Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
- Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
- Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
- A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
- A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
- Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
- Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
- A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
- Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
- Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
- Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
- Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
- Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
- Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
- Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
- Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
- Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
- Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
- Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
- Rotating Pazopanib and Everolimus to Avoid Resistance
- Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
- HYPAZ: Hypertension Induced by Pazopanib
- Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
- Neoadjuvant Pazopanib in Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
- Treatment of Corneal Neovascularization With Topical Pazopanib
- Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
- Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
- Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
- A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
- VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
- Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
- Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
- Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
- Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
- Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
- Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
- Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
- Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
- Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
- Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
- Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
- Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
- Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
- Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Pazopanib in Treating Patients With Metastatic Urothelial Cancer
- Pazopanib in Treating Patients With Recurrent Glioblastoma
- Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
- Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
- Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
- Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
- Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Clinical trials list
click for details